Clinical evaluation of an enamel matrix protein derivative combined with either a natural bone mineral or beta-tricalcium phosphate.
BACKGROUND
The purpose of the present study was to compare the healing of deep intrabony defects following treatment with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) or beta-tricalcium phosphate (beta-TCP).


METHODS
Twenty-four patients with advanced periodontal disease, each of whom displayed one intrabony defect, were randomly treated with a combination of either EMD + NBM or EMD + beta-TCP. Clinical evaluation was performed at baseline and 1 year following therapy.


RESULTS
No differences in any of the investigated parameters were observed at baseline between the two groups. Healing was uneventful in all patients. At 1 year after therapy, the sites treated with EMD + NBM showed a reduction in mean probing depth (PD) from 7.9 +/- 1.0 mm to 3.2 +/- 0.6 mm and a change in mean clinical attachment level (CAL) from 8.8 +/- 1.1 mm to 4.5 +/- 0.6 mm (P < 0.001). In the group treated with EMD + beta-TCP, the mean PD was reduced from 7.8 +/- 1.2 mm to 3.2 +/- 0.9 mm, and the mean CAL changed from 8.8 +/- 1.2 mm to 4.7 +/- 1.2 mm (P < 0.001). In both groups, all sites gained at least 3 mm of CAL. CAL gains of 4 or 5 mm were measured in the majority of the cases (75%), irrespective of treatment modality. No statistically significant differences in terms of PD reductions and CAL gains were observed between the two groups.


CONCLUSIONS
Within the limits of the present study, both therapies resulted in significant PD reductions and CAL gains 1 year after surgery.
Döri
Ferenc
F
Department of Periodontology, Semmelweis University, Budapest, Hungary.
Arweiler
Nicole
N
Gera
István
I
Sculean
Anton
A
D000328:Adult; D000368:Aged; D016301:Alveolar Bone Loss / Q000601:surgery; D001857:Bone Matrix / Q000637:transplantation; D001861:Bone Regeneration / Q000187:drug effects; D018786:Bone Substitutes / Q000627:therapeutic use*; D002130:Calcium Phosphates / Q000627:therapeutic use; D003746:Dental Enamel Proteins / Q000627:therapeutic use*; D003774:Dental Plaque Index; D005260:Female; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000145:classification; D016557:Guided Tissue Regeneration, Periodontal; D006801:Humans; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000627:therapeutic use; D017622:Periodontal Attachment Loss / Q000145:classification / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000145:classification / Q000601:surgery; D014945:Wound Healing / Q000187:drug effects
C077540:Bio-Oss; D018786:Bone Substitutes; D002130:Calcium Phosphates; D003746:Dental Enamel Proteins; D008903:Minerals; C485817:beta-tricalcium phosphate; C109069:enamel matrix proteins